Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen Inc. (BIIB) Stock Moves -0.67%: What You Should Know
10:00pm, Thursday, 14'th Apr 2022 Zacks Investment Research
In the latest trading session, Biogen Inc. (BIIB) closed at $212.55, marking a -0.67% move from the previous day.
INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate
07:38pm, Thursday, 14'th Apr 2022 Zacks Investment Research
INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.
3 Biotech Stocks That Could Help Make You a Fortune
10:00am, Thursday, 14'th Apr 2022 The Motley Fool
Their products could deliver major revenue over time.
Biogen's Aduhelm Crashes the Biotech Sector
07:36am, Wednesday, 13'th Apr 2022
Aduhelm is an Alzheimer's treatment, not a cure. Its quick approval and high price have set off pushback on the whole FDA and Medicare drug process.
U.S. stocks end mostly lower, with Dow, S&P 500 Nasdaq sliding for the week as investors digest Fed plans amid rising yields
12:33am, Saturday, 09'th Apr 2022 MarketWatch
U.S. stock benchmarks end mostly lower Friday, with the technology-laden Nasdaq Composite and S&P 500 closing down, as investors continue to digest the Federal Reserve's commentary on interest rates w
Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know
09:50pm, Friday, 08'th Apr 2022 Zacks Investment Research
In the latest trading session, Biogen Inc. (BIIB) closed at $214.75, marking a +1.47% move from the previous day.
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
05:02pm, Friday, 08'th Apr 2022
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech S
Biogen (BIIB) Down as Medicare Limits Coverage for Aduhelm
12:59pm, Friday, 08'th Apr 2022 Zacks Investment Research
Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.
Biogen (BIIB) Down as Medicare Limits Coverage for Aduhelm
10:32am, Friday, 08'th Apr 2022
Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.
Why Is Biogen (BIIB) Stock in the Spotlight Today?
10:01am, Friday, 08'th Apr 2022
Medicare's decision not to cover the cost of the drug maker's expensive Alzheimer's drug is hitting the company's stock price today. The post Why Is Biogen (BIIB) Stock in the Spotlight Today?
Medicare Will Limit Coverage of Biogen's Alzheimer's Drug to Those in Clinical Trials
10:42pm, Thursday, 07'th Apr 2022
The Centers for Medicare and Medicaid Services on Thursday confirmed it will limit routine payment for Biogen's Aduhelm--designed to treat early-stage Alzheimer's disease--to patients enrolled in appr
Biogen stock edges lower after Medicare restrictions on Aduhelm finalized
05:21pm, Thursday, 07'th Apr 2022
Shares of Biogen Inc. BIIB, +0.92% fell 0.3% in the extended session Thursday after the Centers for Medicare and Medicaid Services, which oversees the Medicare program, said they had finalized their p
3 Healthcare Stocks That Could Help Set You Up for Life
03:15pm, Thursday, 07'th Apr 2022 The Motley Fool
These stocks are full of growth potential.
Value Lurks in Healthcare Sector
01:53pm, Thursday, 07'th Apr 2022
Broadly speaking, the healthcare sector's returns in 2022 are middling. In theory, that shouldn't be the case because the group usually isn't vulnerable to two of the scenarios plaguing markets today:
Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know
10:00pm, Monday, 04'th Apr 2022 Zacks Investment Research
Biogen Inc. (BIIB) closed the most recent trading day at $211.64, moving +0.47% from the previous trading session.
